The Role of JAK Inhibition in Rheumatic Disease

During this interactive course you will be presented with decision trees that offer a case-based look at current treatment guidelines for rheumatoid and psoriatic arthritis, highlighting how various patient demographics can affect therapeutic decisions.

0 Lessons
Take the Course!


The Role of JAK Inhibition in Rheumatic Diseases


April Johnson, MSN, APRN, CNP
Nurse Practitioner
McBride Orthopedic Hospital
Edmond, OK

Barbara Kienzle, BSN, RN
Registered Nurse
Augusta University’s Children’s Hospital of Georgia
Augusta, GA

Target Audience

This activity has been designed to meet the educational needs of rheumatology nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.

Learning Objective and Goal:

Upon completion of this activity, participants should be able to:

  1. Identify any mismatches between recommendations of the American College of Rheumatology and European League Against Rheumatism for the treatment of rheumatoid and psoriatic arthritis and your current practice
  2. Discuss the appropriate role of JAK inhibitors approved for the treatment of rheumatoid and psoriatic arthritis in today’s healthcare climate

Accreditation Statement

The Rheumatology Nurses Society is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).

Participants will receive 0.75 hours of continuing nursing contact hours, including 0.25 pharmacotherapeutic hours, by completing the activity, completing an online evaluation, and receiving a post-test score of 70%.

Disclosure Statement

According to the disclosure policy of RNS, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Relationships are abbreviated as follows: E, Educational planning committee; G, Grant/research support recipient; A, Advisor/review panel member; C, Consultant; S, Stock shareholder; SB, Speaker bureau; PE, Promotional event talks; H, Honoraria; O, Other.

Planners, reviewers, and faculty have disclosed no conflicts of interest related to the content of this education, with the exception of the following:

Barbara Kienzle, BSN, RN, has disclosed the following relevant financial relationship specific to the subject matter of the content included in this educational activity: Mallinckrodt/AB.

Off-Label Product Disclosure

This activity will include a discussion of the following off-label or investigational product: Filgotinib.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE contact hours for your participation, please complete the activity, a post test (achieving a passing score of 70% or greater), and program evaluation. Your certificate can be printed immediately.


This activity is supported by educational grants from Pfizer, AbbVie, and Gilead.